Fig. 2

Mean (a) SAC-TDI (b) change from baseline E-RS total score by baseline SABA use^a. CFB change from baseline, CI confidence interval, ERS Evaluating Respiratory Symptoms: COPD, LS least squares, SABA short-acting β₂-agonist, SAC-TDI self-administered computerised Transition Dyspnoea Index, SAL salmeterol, UMEC umeclidinium, VI vilanterol. ^aMean SABA use was 3.91 puffs/day and 0.39 puffs/day in the high and low SABA use subgroups, respectively